Floatz logo

Daunorubicin

FLT3 Gene Mutation

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the FLT3 Gene Mutation cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Gilteritinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Azacitidine
M.D. Anderson Cancer Center
Phase 2CCC
5-azacytidine
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2CC

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →